Researchers urge radiotherapy for all patients with bone mets

February 13, 2017

(HealthDay)—For patients with bone metastases, those responding to radiotherapy experience greater pain reduction and better quality of life (QOL) at day 10 after radiotherapy, according to a study published online Feb. 9 in JAMA Oncology.

Rachel McDonald, M.D., from Sunnybrook Health Sciences Centre in Toronto, and colleagues used a bone metastases-specific QOL tool to examine QOL at days 10 and 42 after among 298 patients from 23 Canadian centers.

The researchers found that 40.9 and 38.9 percent of patients responded to radiotherapy at day 10 and 42, respectively. Compared with non-responders, patients with a had a greater reduction in (mean reduction, 17.0 versus 1.8; P = 0.002) and pain characteristics (mean reduction, 12.8 versus 1.1; P = 0.002) at day 10; they also had greater improvements in functional interference (mean increase, 11.6 versus 3.6; P = 0.01) and psychosocial aspects (mean, 1.2-point increase in responders versus 2.2-point decrease in non-responders; P = 0.04). Compared with non-responders, responders had significantly greater improvements in physical, emotional, and global domains of the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative when comparing changes in QOL from baseline to day 42 (all P < 0.001).

"A single 8-Gy radiotherapy dose for bone metastases should be offered to all , even those with poor survival," the authors write.

Explore further: Intravenous lidocaine offers alternative for ICU patients' pain

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Intravenous lidocaine offers alternative for ICU patients' pain

February 9, 2017
(HealthDay)—Intravenous lidocaine (IVLI) seems safe for reducing pain among patients in the intensive care unit (ICU) with varying degrees of organ dysfunction, according to research published online Feb. 7 in the Journal ...

Pregabalin significantly improves neuropathic pain

September 9, 2016
(HealthDay)—Pregabalin significantly improves neuropathic pain, irrespective of the time since pain onset, according to a study published online Sept. 2 in Pain Practice.

Rifaximin effective for repeat treatment of IBS with diarrhea

December 27, 2016
(HealthDay)—Repeat treatment with the nonsystemic antibiotic rifaximin is effective in patients with relapsing symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), according to a study published in the December ...

Palliative radiotherapy for bone metastases in elderly patients improves quality of life

April 22, 2013
Giving palliative radiotherapy to elderly patients with painful bone metastases can significantly improve their quality of life, a Dutch researcher told the 2nd Forum of the European Society for Radiotherapy and Oncology ...

Bone-strengthening drug gives pain relief in prostate cancer bone metastases

September 25, 2011
Stockholm, Sweden: Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has ...

Decision regret uncommon after radical prostatectomy, IMRT

August 22, 2016
(HealthDay)—For patients with prostate cancer treated with radical prostatectomy (RP) and post-prostatectomy image-guided intensity-modulated radiotherapy (IG-IMRT), decision regret (DR) is uncommon and occurs more often ...

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.